Ebola: Silver lining emerges amid the clouds

2015-01-18 15:00

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Scientists are making “remarkable progress” in developing a safe, effective Ebola vaccine, says Wits University’s Professor Helen Rees.

She should know. Rees chaired a high-level World Health Organisation (WHO) meeting in Geneva last week, where the progress of three potential – or “candidate” – vaccines was discussed.

Also in attendance were health ministers, ambassadors and scientists. Rees, a vaccinologist and executive director of the Wits Reproductive Health Institute, told City Press on Thursday that the current Ebola outbreak in west Africa had pushed researchers into a corner.

This is the first time in medical history that it has taken scientists mere months to conduct clinical trials on potential vaccines for a highly infectious disease. It takes an average of 12 years for a drug to move from the testing phase in a laboratory to patient use.

“We had no choice but to move with great speed because the virus was spreading quickly, and a great number of people were being infected and dying in a short space of time,” said Rees.

Potential Ebola vaccines have been in the development stage for decades, but there’s never been any urgency to conduct clinical trials because there has not been a widespread outbreak.

All this changed early last year when Liberia, Sierra Leone and Guinea became the epicentre of an outbreak that has already killed more than 8?400 people.

Rees said despite the race against the clock, scientists would not compromise on quality and safety when creating a vaccine.

“We are aware that there might be concerns about pushing speed, but we can assure the world that we will not compromise on quality,” she said.

“We are going to run [Phase 2 and 3] trials in parallel to ensure we do not waste time.

“We are working with regulatory authorities  and data monitoring review boards throughout the process to ensure everything is done to the book.”

The outbreak seems to have tapered off in some areas and the scientists’ haste also relates to making immediate use of available opportunities.

Updated figures from the WHO reveal that the number of confirmed Ebola cases have dropped in Guinea, Liberia and Sierra Leone.

“We have to get into the field very quickly to do these clinical trials, because if there are very few cases of Ebola, it’s going to be difficult to test whether the vaccines work or not,” said Rees.

“We have three candidate vaccines, with more in the pipeline. Two vaccines – one manufactured by GlaxoSmithKline and the other by Merck – have already undergone the first phase of testing, which looks at safety and immunogenicity [to induce immune response].

“Both vaccines have been found to be safe and will now move to the second and third trial.

“Safety and immunogenicity will be tested [in the general population] during the Phase 2 trial and efficacy in the third trial,” she explained.

Rees estimated that this process should take about six months.

The trials are set to take place where they are needed most – in Liberia, Sierra Leone and Guinea.

Three ways in which to get the vaccine

Professor Helen Rees says vaccine researchers are looking at three trial designs – and one of each will be rolled out in Sierra Leone, Guinea and Liberia over the next few weeks.

Liberia: “Vaccines will be tested against each other and against a control [placebo],” she says.

Sierra Leone: “Vaccine doses will be given to frontline workers and there will be no placebo.

“Effectiveness will be determined by looking at whether there are fewer cases of Ebola among workers who are vaccinated earlier, compared with those who are vaccinated later.”

Guinea: Rees says the “ring vaccination” method will be used in Guinea, which was the site of the first reported Ebola case during the current outbreak. In an article in the journal EMBO Molecular Medicine, a team of researchers reported late last year that they believed the origin of the outbreak was a single tree in the village of Meliandou, Guinea. A bat colony living in the tree was blamed for infecting two-year-old Emile Ouamouno in December 2013. The toddler later died.

Ring vaccination involves reacting when a case is reported, then vaccinating whoever has come into contact with the infected person. – Zinhle Mapumulo

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.